Stella Sarraf founded drug discovery company Spinogenix in 2016 with a goal of finding a better way to treat neurodegenerative disorders—particularly Alzheimer’s Disease. Her approach looks at the brain’s synapses, which are the structures that allow our neurons to, effectively, talk to each other. “We have a small molecule drug in clinical development working at restoring those synapses, those connections that can stop working,” Sarraf told ForbesWomen editor Maggie McGrath in a recent interview. “When you restore those connections, you can regain function. So our hope is that we can restore memory.”

Thank you Maggie McGrath for the invitation to share more about the mission of Spinogenix and the ForbesWomen newsletter for publishing this follow up.